Regulatory Considerations DMEG to Review Health Canada’s Draft Guidance
Date: August 4, 2026
Thank you to the Regulatory Considerations DMEG for sharing this update.
Health Canada published a Draft guidance on decentralized clinical trials. This is part of Health Canada’s effort to modernize clinical trial regulation to allow for new trial types and designs. The guidance applies to phase I-IV trials involving pharmaceuticals, biologics and radiopharmaceuticals intended for human use. It does not apply to medical devices, natural health projects or foods for special dietary purposes.
The ACDM Regulatory Considerations DMEG will be reviewing the draft guidance and publishing a summary of the points that impact data managers. In the interim you can read the draft guidance here: Health Canada Draft guidance on decentralized clinical trials or download here.
Meet the DMEG here
Explore More News

HMA/EMA joint Big Data Steering Group: Big Data Workplan 2023-2025
The joint HMA-EMA Big Data Steering Group (BDSG) have released their latest workplan, . . .
Read More

ACT EU PA04 – Multi-stakeholder Workshop on ICH E6 R3
As part of the Accelerating Clinical Trials in the EU (ACT EU) multi-annual workplan . . .
Read More

European Medicine’s Agency – Reflection paper on the use of artificial intelligence in the lifecycle of medicines
The EMA has opened a public consultation on a reflection paper presenting views . . .
Read More

Welcome Instem as a new corporate member
The ACDM: Association for Clinical Data Management is delighted to welcome Instem as a new . . .
Read More

Regulatory Considerations Expert Group reviews draft FDA Guidance
The ACDM Regulatory Considerations Expert Group have reviewed and submitted comments on . . .
Read More

ICH GCP E6 Revision 3 is here. Regulatory Considerations Expert Group to review
The R&D industry, especially those that are working on clinical trials, have been . . .
Read More

Welcome Algorics as a new corporate member
The ACDM: Association for Clinical Data Management is delighted to welcome Algorics as a . . .
Read More

Consultation response on legislative proposals for clinical trials
The MHRA have published the public consultation response to the proposals to reform the . . .
Read More

New MHRA Guidance
The MHRA have published new guidance on ‘Software and Artificial Intelligence (AI) as a . . .
Read More

FDA Guidance for Industry
The FDA has issued a final guidance to provide information on risk-based approaches to . . .
Read More

Guideline on computerised systems and electronic data in clinical trials
The European Medicines Agency (EMA) have published the new guidelines on computerised . . .
Read More

Welcome IROS – Insights Research Organization & Solutions as a new corporate member
The ACDM: Association for Clinical Data Management is delighted to welcome IROS – Insights . . .
Read More